Competing interests
honororia
ONCOLOGY, BANG, CROSS, EMD
A potential competing interest is the provision of study drug regorafenib by BAYER.Kohei Shitara reports receiving personal fees for advisory roles from Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Merck Pharmaceutical, Taiho Pharmaceutical, Astellas, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan, and Janssen; receiving honoraria (lecture fee) from Takeda, Bristol-Myers Squibb and Janssen; and receiving research funding from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Medi Science, Eisai and Amgen, outside the submitted work.Keun-Wook Lee reports receiving grants from Ono pharmaceutical, AstraZeneca, Merck Sharp and Dohme, Merck KGaA, Pfizer, BeiGene, Zymeworks, ALX Oncology, Astellas, Macrogenics, Five Prime Therapeutics, Seagen, Bolt therapeutics, Trishula therapeutics, Oncologie, Pharmacyclics, Daiichi Sankyo, Taiho Pharmaceutical, InventisBio, Leap therapeutics, MedPacto, LSK BioPharma, Green Cross Corp, ABLBIO, Y-BIOLOGICS, Genexine, Metafines (to his institution for conducting clinical trials), personal fees from Metafines, Bayer, Daiichi Sankyo, Merck Sharp and Dohme, Bristol Myers Squibb, Vifor Pharma (consultation) and Ono pharmaceutical, Boryung (honorarium) outside the submitted work.Thierry Alcindor reports receiving consulting/advisory fees from Merck, Bayer, BMS, Astrazeneca, Astellas Scientific and Medical Affairs Inc and research funding from epizyme, emd serono, karyopharm therapeutics, springworks therapeutics, astellas pharma and deciphera.Tanios Bekaii-Saab reports receiving research funding to institution from Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS; Consulting fees to institution from Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGA and Merck; personal consulting fees from Stemline, AbbVie, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, Astra Zeneca, Deciphera, Zai Labs, MJH Life Sciences, Aptitude Health, Illumina and Foundation Medicine.Katrin Marie Sjoquist reports receiving honororia from AMGEN, BMS, Ipsen, Merck and SERVIER; research funding to institution from Bayer; consulting/advisory role for Competitive Drug Development International.Yung-Jue Bang reports consulting on the advisory board for MSD, Merck Serano, Daiichi-Sankyo, Astellas, Alexo Oncol, Samyang Biopharm, Hanmi, Daewoong and Amgen; receiving research grants from Genentech/Roche, MSD, Merck Serano, Daiichi Sankyo, Astellas and Amgen.The other authors declare they have no competing interests.